News
USFDA issues warning letter to Glenmark's Goa manufacturing facility
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
- By IPP Bureau
| November 24, 2022
The USFDA has issued a warning letter to the Glenmark Pharmaceuticals Limited Goa (India) manufacturing facility.
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.
The company is committed to work along with the USFDA to implement all the necessary corrective actions required to address the concerns at the earliest. The company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.
On 27th August, 2022, Glenmark Pharmaceuticals informed about the Official Action Indicated (OAI) status of the company’s Goa (India) manufacturing facility by USFDA following the inspection conducted in May 2022.
_256_275.jpg)
.jpg)
